Is there efficacy of Immune-checkpoints in patients with Non Small Cell lung Cancer with EGFR common mutations?
Best insight from top research papers
Immune checkpoint inhibitors (ICIs) show efficacy in Non-Small Cell Lung Cancer (NSCLC) patients with EGFR mutations. Studies indicate that ICIs combined with chemotherapy and anti-angiogenic drugs are effective for EGFR-TKI resistant NSCLC patients, providing better prognosis compared to monotherapy or chemotherapy alone . Furthermore, patients with EGFR mutations who received ICIs combined with anti-angiogenic therapy had longer progression-free survival (PFS) and overall survival (OS) compared to those receiving ICIs with chemotherapy . However, mutational signatures derived from targeted sequencing assays may not reliably predict ICI efficacy in NSCLC, suggesting that whole exome or genome sequencing may be more suitable for such predictions . Overall, ICIs, especially in combination therapies, demonstrate efficacy in NSCLC patients with EGFR mutations.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| Combination therapy involving immune checkpoint inhibitors (ICIs) shows promise in NSCLC patients with EGFR mutations post-targeted therapy resistance, aiming for individualized treatment to maximize efficacy. | |
08 Jun 2023 | EGFR-TKIs and ICIs show efficacy in treating recurrent NSCLC after surgery, with no significant difference in overall survival between them, indicating potential effectiveness in EGFR-mutated NSCLC. |
| Patients with EGFR mutations in NSCLC benefitted from immune checkpoint inhibitors (ICIs) combined with anti-angiogenic therapy, showing improved progression-free survival and overall survival compared to chemotherapy combinations. | |
| Immune checkpoint inhibitors show limited efficacy in NSCLC patients with previous EGFR mutations. However, combining them with chemotherapy and anti-angiogenic drugs improves outcomes in EGFR-TKI-resistant cases. | |
| Not addressed in the paper. |
Related Questions
What genetic mutations are most commonly associated with the development of Non-small cell lung cancer cancer?5 answersDeleterious mutations in the ATM gene are frequently associated with the development of Non-small cell lung cancer (NSCLC). These mutations define a distinct subset of NSCLC with unique clinicopathologic, genomic, and immunophenotypic features, including associations with female sex, smoking history, non-squamous histology, and higher tumor mutational burden. Additionally, co-occurring mutations in KRAS, STK11, and ARID2 are significantly enriched in ATM-mutant NSCLCs, while TP53 and EGFR mutations are more common in ATM wild-type cases. Furthermore, patients with concurrent ATM/TP53 mutations exhibit improved response rates and progression-free survival with certain therapies. These findings highlight the significant role of ATM mutations in the pathogenesis and clinical outcomes of NSCLC.
How does EGFR mutation affect NSCLC treatment?4 answersEGFR mutation plays a significant role in the treatment of non-small cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitors (TKIs) have been developed as targeted therapies for NSCLC patients with EGFR mutations, leading to improved treatment prospects and prognosis. However, the efficacy of conventional EGFR-TKIs and optimal treatments for patients with EGFR compound mutations or concomitant mutations are still largely unknown. Uncommon EGFR mutations, such as G719X, S768I, and L861Q, have been found to be sensitive to afatinib, a second-generation oral EGFR-TKI. On the other hand, EGFR exon 20 insertions (EGFR ex20ins) mutation, which is a rare mutation, has shown low sensitivity to most EGFR-TKIs. Immune checkpoint inhibitors (ICIs) have revolutionized NSCLC treatment, and even patients with EGFR-mutated NSCLC may choose an ICI after failure of EGFR-TKI treatment. Discontinuation of ICI therapy due to immune-related adverse events (irAEs) does not adversely affect the prognosis of patients with EGFR-mutant NSCLC.
What is the impact of other genetic abnormalities on EGFR mutation-positive lung cancer?4 answersEGFR mutation-positive lung cancer is not solely driven by EGFR mutations, but also by other genetic abnormalities. Co-occurring alterations in tumor suppressor genes (TSGs) have been found to impact patient outcomes in EGFR-mutant NSCLC. These alterations, such as mutations in TP53 and additional TSGs, are associated with worse progression-free survival (PFS) and overall survival (OS) in patients treated with EGFR tyrosine kinase inhibitors (TKIs). Furthermore, the presence of co-occurring genomic alterations, including TP53 mutations, has been identified as a negative prognostic biomarker, potentially leading to earlier resistance to targeted therapy. It has been suggested that these additional TSG alterations, rather than TP53 mutational status alone, drive the inferior outcomes in EGFR/TP53-mutant NSCLC. Understanding the impact of these genetic abnormalities is crucial for optimizing treatment strategies and predicting EGFR-TKI efficacy in EGFR mutation-positive lung cancer patients.
What is the evidence gap for perioperative immunotherapy in resectable non-small cell lung cancer?5 answersPerioperative immunotherapy for resectable non-small cell lung cancer (NSCLC) has shown promising results, but there are still some evidence gaps that need to be addressed. The available evidence suggests that more studies are needed to evaluate long-term patient outcomes and provide a stronger foundation for the use of these treatments. Clinical trials have demonstrated the efficacy of immune checkpoint inhibitors (ICIs) in the neoadjuvant and adjuvant settings, leading to improved clinical outcomes. However, further research is needed to identify optimal types of perioperative immunotherapy and biomarkers for patient selection. Phase 3 studies have reported survival benefits of perioperative immunotherapy, but overall survival did not differ significantly between treatment groups in one analysis. The utility of ICIs in preoperative NSCLC patients has been explored, but the predictive efficacy of potential biomarkers is still being investigated. In summary, there is a need for more studies evaluating long-term outcomes, optimal treatment types, and predictive biomarkers in perioperative immunotherapy for resectable NSCLC.
What are the challenges and opportunities in the treatment of EGFR mutation in non-small cell lung cancer?5 answersThe treatment of EGFR mutation in non-small cell lung cancer (NSCLC) presents both challenges and opportunities. One challenge is the development of resistance to EGFR tyrosine kinase inhibitors (TKIs) due to the emergence of novel mutations such as T790M. However, the third-generation EGFR-TKI osimertinib has shown promising results in targeting both EGFR and T790M mutations, with reduced toxicity compared to earlier generations. Another challenge is the detection of EGFR mutations in tumor tissues, which can be addressed by using mutation-specific probes for visualizing EGFR mutation-positive parts of NSCLC tissues. Identifying the targeted mutations in NSCLC is crucial for treatment planning, and patients with EGFR or ALK mutations have been shown to have a longer life expectancy when receiving targeted therapy. Overall, the development of targeted therapies and the use of mutation-specific probes offer opportunities for improving the treatment outcomes of EGFR mutation in NSCLC.
How predictive is PD-L1 as an immunohistochemical marker for the efficacy of checkpointinhibitors in non-small cell lung cancer?5 answersPD-L1 expression detected by immunohistochemistry (IHC) is used as a predictive biomarker for the efficacy of checkpoint inhibitors in non-small cell lung cancer (NSCLC). However, the predictive value of PD-L1 varies between tumor types and has limitations. PD-L1 expression is not sufficient on its own to select patients who may benefit from immunotherapy. PD-L1 testing must be carefully implemented for clinical decision-making. There are several open issues related to PD-L1 testing, including the use of different staining platforms and antibodies, the type of cells in which PD-L1 is assessed, and the thresholds used for PD-L1 positivity. Therefore, newer biomarkers such as tumor mutation burden and neoantigens are being explored as more reliable alternatives to PD-L1 for guiding treatment selection with checkpoint inhibitors in NSCLC.